Lexicon Pharmaceuticals (LXRX) Equity Ratio (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Equity Ratio data on file, last reported at 0.75 in Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.75, up 82.58% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.75 (up 82.58% YoY), and the FY2025 annual result was 0.58, up 18.86% from the prior year.
• Equity Ratio rose to 0.75 in Q1 2026 per LXRX's latest filing, from 0.58 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.75 in Q1 2026 and troughed at 0.41 in Q4 2023.
• A 5-year average of 0.59 and a median of 0.58 in 2025 frame the typical range for Equity Ratio.
• The sharpest annual moves came in 2025 and 2026: Equity Ratio plunged 40.3% in 2025, then soared 82.58% in 2026.
• A 5-year view of Equity Ratio shows it stood at 0.6 in 2022, then tumbled by 32.68% to 0.41 in 2023, then advanced by 20.51% to 0.49 in 2024, then advanced by 18.86% to 0.58 in 2025, then climbed by 29.81% to 0.75 in 2026.
• Business Quant data shows LXRX's Equity Ratio at 0.75 in Q1 2026, 0.58 in Q4 2025, and 0.58 in Q3 2025.